Home » News » Clinical Intelligence » Amsterdam deemed a good choice as EMA’s new home, but transition will not be easy

Amsterdam deemed a good choice as EMA’s new home, but transition will not be easy

Monday, December 4, 2017

The EMA, a multi-national regulatory agency that serves more than 500 million people living in Europe, will relocate from London to Amsterdam as a direct result of Britain’s vote to leave the European Union (EU), known as Brexit. While the move will be devastating for Britain’s pharmaceutical and health sciences industries, it will bring nearly 1,000 new jobs and an injection of capital to Amsterdam, which will become the EMA’s new home when the U.K. officially leaves the EU in March 2019. Overall, 19 European cities bid on the highly sought-after spot. After a complex voting process, a tie-breaking draw of lots crowned Amsterdam the winner over Milan. 

Innovation, evidence and adoption of mobile health apps accelerates

The impact of digital health on patient care is accelerating with the increasing adoption of mobile health apps and wearable sensors. By all indications, this trend is beneficial to those involved with clinical research trials, with perhaps the most significant impact for patients. However, the technology is not without its share of concerns and questions. Findings are the result of a new study conducted by The IQVIA Institute for Human Data Science, formerly QuintilesIMS. The study, The Growing Value of Digital Health: Evidence and Impact on Human Health and the Healthcare System, was produced independently as a public service, without industry or government funding, and it is the most comprehensive study of its kind conducted to date.

 

To read the full articles for this issue of The CenterWatch Weekly, please click here for subscription information.

Related Posts